EUVIMEDEUVIMED entdecken
Crossref

Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 Antibodies

Alexandra Jungova, Martin Stork, Ivan Spicka, Jakub Radocha, Jiri Minarik, Petr Pavlicek, Jana Mihalyova, Ludek Pour, Jan Straub, Vladimir Maisnar, Tomas Pika, Tereza Dekojova und 19 weitere

Clinical Lymphoma Myeloma and Leukemia · 2025

DOI: 10.1016/j.clml.2025.10.022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Alexandra Jungova und 30 weiteren Autor:innen. Beteiligte Einrichtung: Hematology and Oncology Department, Charles University Hospital, Pilsen, Czech Republic. Electronic address: jungovaa@fnplzen.cz. Hauptthemen laut MEDLINE: Multiple Myeloma, Bortezomib, Antineoplastic Combined Chemotherapy Protocols, Lenalidomide. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Ministerstvo Zdravotnictví Ceské Republiky, European Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Multiple myeloma (MM) is a hematologic malignancy defined by clonal proliferation of plasma cells in the bone marrow. The introduction of bortezomib, a proteasome inhibitor, has significantly improved outcomes in MM, becoming a cornerstone of therapy since its approvals for relapsed/refractory MM in 2003 and newly diagnosed MM (NDMM) in 2008. Bortezomib induces apoptosis in malignant plasma cells by disrupting protein degradation pathways. RATIONALE: Triplet regimens combining bortezomib with immunomodulatory drugs, alkylating agents, and corticosteroids have shown high efficacy, especially in NDMM patients ineligible for autologous stem cell transplant (ASCT). However, clinical trials often underrepresent real-world populations, with 40% to 50% of MM patients not meeting eligibility criteria. METHODS: To address this evidence gap, we performed a retrospective analysis of national real-world data from the Czech Republic, assessing 17 years of experience with bortezomib-based triplet regimens in transplant-ineligible NDMM patients. CONCLUSIONS: This study provides critical insights into the long-term effectiveness and applicability of bortezomib-based therapies outside of controlled trial settings, offering a more comprehensive understanding of treatment outcomes in routine clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaBortezomibAntineoplastic Combined Chemotherapy ProtocolsLenalidomideHumansMaleFemaleAgedDexamethasoneMiddle AgedRetrospective StudiesTreatment OutcomeAged, 80 and overAdultADP-ribosyl Cyclase 1

Substanzen

BortezomibDexamethasoneLenalidomideADP-ribosyl Cyclase 1

Autor:innen und Institutionen

  • Hematology and Oncology Department, Charles University Hospital, Pilsen, Czech Republic. Electronic address: jungovaa@fnplzen.cz.
  • Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • 1st Medical Department - Clinical Department of Hematology of the First Faculty of Medicine and General Teaching Hospital Charles University, Prague, Czech Republic.
  • 4th Department of Medicine - Hematology, Charles University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic.
  • Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.
  • Department of Internal Medicine and Haematology 3rd Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic.

Förderung

  • Ministerstvo Zdravotnictví Ceské Republiky
  • European Commission

Zitieren

APA

Jungova, A., Stork, M., Spicka, I., Radocha, J., Minarik, J., Pavlicek, P., Mihalyova, J., Pour, L., Straub, J., Maisnar, V., Pika, T., Dekojova, T., Soukup, J., Popkova, T., Mensikova, K., Sedlák, F., Pospiskova, J., Boichuk, I., Krhovska, P., …, & Hajek, R. (2025). Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 Antibodies. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.10.022

Vancouver

Jungova A, Stork M, Spicka I, Radocha J, Minarik J, Pavlicek P, et al. Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 Antibodies. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.10.022

BibTeX
@article{Jungova2025,
  author = {Jungova, Alexandra and Stork, Martin and Spicka, Ivan and Radocha, Jakub and Minarik, Jiri and Pavlicek, Petr and Mihalyova, Jana and Pour, Ludek and Straub, Jan and Maisnar, Vladimir and Pika, Tomas and Dekojova, Tereza and Soukup, Jan and Popkova, Tereza and Mensikova, Klara and Sedlák, Frantisek and Pospiskova, Jana and Boichuk, Ivanna and Krhovska, Petra and Stopka, Tomas and Jindra, Pavel and Jelínek, Tomas and Knechtová, Zdenka and Capounova, Vladimira and Latal, Vojtech and Muronova, Ludmila and Heindorfer, Adriana and Ullrychova, Jana and Sykora, Michal and Kessler, Petr and Hajek, Roman},
  title = {Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 Antibodies},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  doi = {10.1016/j.clml.2025.10.022}
}
Kostenlos starten →